News | March 24, 2025
AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
Subscribe To Our Newsletter & Stay Updated
